Literature DB >> 7844377

Exacerbation of acute and chronic murine tuberculosis by administration of a tumor necrosis factor receptor-expressing adenovirus.

L B Adams1, C M Mason, J K Kolls, D Scollard, J L Krahenbuhl, S Nelson.   

Abstract

Tumor necrosis factor (TNF) plays a pivotal role in inflammatory phenomena that culminate in either pathogenesis or resistance in mycobacterial disease. The regulatory role of TNF in murine tuberculosis was examined by administering a recombinant adenovirus encoding a fusion protein consisting of the human 55-kDa TNF receptor extracellular domain and the mouse IgG heavy chain domain (AdTNFR). During acute infections with Mycobacterium tuberculosis, AdTNFR pretreatment induced elevated mycobacterial burdens of 1 log10 in the tissues of H37Ra-infected mice and 2 log10 (spleen and liver) and 4 log10 (lungs) in H37Rv-infected mice. In mice infected chronically with H37Rv, AdTNFR treatment induced a 3-log10 increase of M. tuberculosis in the lungs, in which a tuberculous bronchopneumonia developed with numerous acid-fast bacilli visible in alveoli and bronchi. Administration of AdTNFR may serve as a useful model for studying the pathogenesis and chemotherapy of progressive primary tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7844377     DOI: 10.1093/infdis/171.2.400

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Tumor necrosis factor (TNF) and a TNF-mimetic peptide modulate the granulomatous response to Mycobacterium bovis BCG infection in vivo.

Authors:  D R Roach; H Briscoe; K Baumgart; D A Rathjen; W J Britton
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

Review 2.  Tuberculosis: latency and reactivation.

Authors:  J L Flynn; J Chan
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

Review 3.  Role of lymphotoxin in experimental models of infectious diseases: potential benefits and risks of a therapeutic inhibition of the lymphotoxin-beta receptor pathway.

Authors:  Thomas W Spahn; Hans-Pietro Eugster; Adriano Fontana; Wolfram Domschke; Torsten Kucharzik
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

4.  Reactivation of latent tuberculosis: variations on the Cornell murine model.

Authors:  C A Scanga; V P Mohan; H Joseph; K Yu; J Chan; J L Flynn
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

5.  Posttreatment reactivation of tuberculosis in mice caused by Mycobacterium tuberculosis disrupted in mce1R.

Authors:  Chan-Ick Cheigh; Ryan Senaratne; Yujiro Uchida; Nicola Casali; Lon V Kendall; Lee W Riley
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

6.  Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation.

Authors:  Elizabeth F Redente; David M Higgins; Lori D Dwyer-Nield; Ian M Orme; Mercedes Gonzalez-Juarrero; Alvin M Malkinson
Journal:  J Leukoc Biol       Date:  2010-04-01       Impact factor: 4.962

7.  Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine.

Authors:  L B Adams; I Sinha; S G Franzblau; J L Krahenbuhl; R T Mehta
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

8.  A tumor necrosis factor mimetic peptide activates a murine macrophage cell line to inhibit mycobacterial growth in a nitric oxide-dependent fashion.

Authors:  W J Britton; N Meadows; D A Rathjen; D R Roach; H Briscoe
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

9.  Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections.

Authors:  Maria L Olleros; Reto Guler; Dominique Vesin; Roumen Parapanov; Gilles Marchal; Eduardo Martinez-Soria; Nadia Corazza; Jean-Claude Pache; Christoph Mueller; Irene Garcia
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

10.  Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans.

Authors:  Heiko Bruns; Christoph Meinken; Philipp Schauenberg; Georg Härter; Peter Kern; Robert L Modlin; Christian Antoni; Steffen Stenger
Journal:  J Clin Invest       Date:  2009-04-20       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.